Featured Research

from universities, journals, and other organizations

UCSD To Investigate A Genetic Approach To Managing High Blood Pressure

Date:
September 12, 2001
Source:
University Of California - San Diego
Summary:
Whether subtle genetic variations among patients with high blood pressure (hypertension) can predict treatment effectiveness is the focus of a new research effort at the University of California, San Diego (UCSD) School of Medicine. This is among the nation’s first federally-funded studies in the emerging field of individualized medicine or "pharmacogenomics," with therapy tailored to a person’s own genetic profile.

Whether subtle genetic variations among patients with high blood pressure (hypertension) can predict treatment effectiveness is the focus of a new research effort at the University of California, San Diego (UCSD) School of Medicine. This is among the nation’s first federally-funded studies in the emerging field of individualized medicine or "pharmacogenomics," with therapy tailored to a person’s own genetic profile.

Related Articles


Funded by a $11.6 million, four-year grant from the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH), the project will team UCSD with Celera Genomics, the company that recently identified and published the sequence of the human genome.

“Why some people respond to blood pressure medications and others don’t has always puzzled physicians,” said project director Daniel T. O’Connor, M.D., UCSD professor of medicine, and a hypertension and kidney disease specialist at UCSD and the Veterans Affairs San Diego Healthcare System. “We believe that a substantial part of that variability is the result of differences in genes that either metabolize drugs or are the target of drugs.”

The goal of pharmacogenomics research is to move beyond the "one-size-fits-all" approach to drug therapy and allow the development of individualized treatment plans based on genetic profiles. Using genetic indicators, physicians and pharmacists can determine in advance which drugs will work best for specific individuals and which are more likely to cause harmful side effects, and prescribe the most effective therapies.

“This research represents the future of medicine and how we will manage disease in the 21st century,” said Edward W. Holmes, M.D., vice chancellor for Health Sciences and dean, UCSD School of Medicine. “With ongoing investigations in the new scientific discipline of pharmacogenomics, we hope to better understand how individual variations in patient DNA can influence disease progression and treatment response.”

While most humans share 99.9 percent of the same genetic sequence, scientists are discovering differences located within the genome (the DNA or hereditary material) in cells throughout the body.

For the complex task of identifying and genotyping genetic variations, called single nucleotide polymorphisms (“SNPs,” pronounced “snips”), the Genomics Core for this program will be run by Celera Genomics, the company that recently identified and published the sequence of the human genome. UCSD will collect DNA samples from more than 800 normal and hypertensive patients and send those samples to Celera for SNP identification and genotyping.

“We are very pleased that Celera and the clinical researchers at UCSD can work together to begin understanding how variations in the human genome can help explain why these kinds of differences exist and how to harness them so physicians can treat individual patients and not statistical averages,” said J. Craig Venter, Ph.D., Celera’s president and chief scientific officer.

The UCSD team will begin by studying human subjects, monitoring changes in blood flow, blood pressure, release of adrenaline and other indicators. DNA from these individuals will be sent to Celera, which will locate and genotype the SNPs within each individual’s genome. Then, UCSD researchers will look at the association between identified genetic variants and particular drug responses in each individual.

“Once we discover those particular variants that seem to be the culprits, we’ll study them in test tubes,” O’Connor said. “Further studies in mice will help us understand the mechanism whereby the genetic variant gives rise to a specific trait, or drug response.”

Finally, clinical trials will be conducted to determine if specific SNPs can predict therapeutic drug responses.

All over the world, research universities and biotechnology companies are searching for new SNPs and trying to determine their function within the body. Much of that research focuses on studies of genes that metabolize drugs, i.e. how the body absorbs medication and eliminates it from the body. The UCSD effort focuses on what happens after a blood pressure drug reaches its target gene within the body.

The UCSD pharmacogenomics project is part of the National Institute of General Medical Sciences NIH Pharmacogenetics Research Network and Knowledge Base. This nationwide research effort oversees investigations at UCSD and 13 additional research centers, with emphasis on a variety of medical conditions including cardiovascular disease, cancer prevention and treatment, asthma, and depression.

The NIGMS notes that at the heart of their Pharmacogenetics Research Network is a shared information library called “PharmGKB,” into which network researchers deposit results they collect. Contents of the library will be accessible to all scientists, with the goal of forging new links between gene variation and drug response.

In addition to O’Connor, UCSD researchers who will participate in the pharmacogenomics studies are Paul Insel, M.D., professor of pharmacology and medicine; Lewis J. Rubin, M.D., professor of medicine; Jason X. Yuan, M.D., Ph.D., associate professor of medicine; Robert J. Parmer, M.D., professor of medicine; Michael G. Ziegler, M.D., professor of medicine; Nicholas Schork, Ph.D., professor of psychiatry; Palmer W. Taylor, Ph.D., professor and chair, Department of Pharmacology; Sushil K. Mahata, Ph.D., associate professor of medicine; Anthony Wynshaw-Boris, M.D., Ph.D., assistant professor of neurosciences and pediatrics; and John Ross, M.D., professor of medicine. Additional researchers include Emily S. Winn-Deen, Ph.D., director of SNP R&D at Celera Genomics and Michael Lipkowitz, M.D., Mt. Sinai School of Medicine.


Story Source:

The above story is based on materials provided by University Of California - San Diego. Note: Materials may be edited for content and length.


Cite This Page:

University Of California - San Diego. "UCSD To Investigate A Genetic Approach To Managing High Blood Pressure." ScienceDaily. ScienceDaily, 12 September 2001. <www.sciencedaily.com/releases/2001/09/010906072057.htm>.
University Of California - San Diego. (2001, September 12). UCSD To Investigate A Genetic Approach To Managing High Blood Pressure. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2001/09/010906072057.htm
University Of California - San Diego. "UCSD To Investigate A Genetic Approach To Managing High Blood Pressure." ScienceDaily. www.sciencedaily.com/releases/2001/09/010906072057.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Nurse Nina Pham Cured of Ebola

Texas Nurse Nina Pham Cured of Ebola

AFP (Oct. 25, 2014) — An American nurse who contracted Ebola while caring for a Liberian patient in Texas has been declared free of the virus and will leave the hospital. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins